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 Patient: Male, 21
 Final Diagnosis: NUT midline carcinoma
 Symptoms: Fatigue • fever • pain
 Medication: Romidepsin
 Clinical Procedure: Chemotherapy
 Specialty: Oncology
 Objective: Rare disease
 Background: NUT midline carcinoma (NMC) is a rare, highly lethal malignancy that results from a chromosome transloca-
tion and mostly arises in the midline organs. To date, no treatment has been established. Most patients re-
ceive combinations of chemotherapy regimens and radiation, and occasionally subsequent resection; never-
theless, patients have an average survival hardly exceeding 7 months.
 Case Report: A 21-year-old patient was admitted to our division with a large mediastinal mass with lung nodules, multiple 
vertebral metastases, and massive nodal involvement. In a few days, the patient developed a superior vena 
cava syndrome and an acute respiratory failure. Due to the rapid course of the disease, based on preliminary 
histology of poorly differentiated carcinoma, a dose-dense biweekly chemotherapy with paclitaxel, ifosfamide, 
and cisplatin was started. In the meantime, the diagnosis of NMC was confirmed. A surprising clinical benefit 
was obtained after the first cycle of chemotherapy, and after 6 cycles a PET-CT scan showed a very good re-
sponse. At this point, radiotherapy was started but the disease progressed outside of the radiation field. The 
patient entered into a compassionate use protocol with Romidepsin, but a PET/CT scan after the first course 
showed disease progression with peritoneal and retroperitoneal carcinosis. A treatment with Pemetrexed was 
then started but the patient eventually died with rapid progressive disease.
 Conclusions: Our case history adds some interesting findings to available knowledge: NMC can be chemosensitive and ra-
diosensitive. This opens the possibility to study more aggressive treatments, including high-dose consolidation 
chemotherapy and to evaluate the role of biological agents as maintenance treatments.
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Background
NUT midline carcinoma (NMC) is a rare, highly lethal malig-
nancy that results from a chromosome translocation and aris-
es in the midline organs. The most common translocation is 
the t(15;19)(q14;p13.1) with bromodomain-containing pro-
tein 4 (BRD4)-NUT oncogene expression [1,2], but less fre-
quently, the NUT gene is fused to a different gene, the bro-
modomain-containing protein 3 (BRD3) gene with the t(15;9)
(q14;q34). Moreover, a novel fusion oncogene involving the 
Human Nuclear SET domain-containing protein 3 (NSD3) and 
the NUT protein has been recently described [3]. It has been 
suggested that the fusion proteins block epithelial-squamous 
differentiation, maintaining the proliferation of immature neo-
plastic elements [4].
In 1991, Kubonishi et al. described the first case of NUT mid-
line cancer in a woman with a presumed thymic carcinoma 
refractory to chemotherapy and radiotherapy [5]. In that case, 
diagnosis was retrospectively made, because NMC was only 
identified as a distinct clinic-pathological entity at the begin-
ning of the last decade [6,7]. Currently, the tumour is usual-
ly diagnosed by fluorescence in situ hybridization (FISH) or by 
demonstrating >50% nuclear staining with the now available 
NUT monoclonal antibody, which has proven to be highly spe-
cific and sensitive for the diagnosis of NMC [8,9].
To date, there is no still established treatment for NMC. Most 
patients receive combinations of multidrug chemotherapy reg-
imens and radiation, and occasionally subsequent resection. 
Anthracycline, cisplatin, gemcitabine, vinorelbine, and tax-
ane-based chemotherapies have been introduced [10,11], but 
durable responses are lacking and patients have an average 
survival hardly exceeding 7 months [12,13]. On the basis of 
the involvement of bromodomain-containing NUT fusion pro-
teins that cause aberrant histone acetylation and blockade of 
differentiation, histone deacetylase inhibitors and bromodo-
main inhibitors are under investigation in clinical trials [14,15].
In our case report we describe a surprising clinical response 
to dose-dense chemotherapy with paclitaxel, ifosfamide, and 
cisplatin.
Case Report
A 21-year-old patient was seen by a family practitioner for a 
1-month history of fatigue, fever, and increasing right-sided 
chest pain. Medical and family histories were unremarkable 
with no specific risk factors. The first chest radiograph per-
formed showed a right superior lobe atelectasia and a widen-
ing of the mediastinum, suggestive of a hilar mass.
Following a rapid and progressive worsening of chest pain and 
the appearance of palpable supraclavicular and axillary lymph 
nodes, on day +7 from the first physical examination, the pa-
tient was admitted to our division. A total-body CT scan re-
vealed a large (13.5×8 cm) right anterior upper mediastinal 
mass with extension into the right lobe, right lung nodules of 
less than 1.5 cm in size, multiple vertebral tumour infiltrates, 
and massive nodal involvement to the right supraclavicular, 
axillary, and mediastinal regions (Figure 1). Multiple focal ar-
eas of fluorodeoxyglucose uptake were documented in all the 
abnormal sites by positron emission tomography (PET). A core 
biopsy of a supraclavicular lymph node showed a poorly dif-
ferentiated carcinoma with a high mitotic index.
In few days the patient rapidly progressed with clinical signs 
and symptoms of a superior vena cava syndrome (VCS), which 
was promptly treated with steroids and placement of a caval 
stent. On day +25 the clinical conditions worsened with an 
acute respiratory failure due to a complete tracheal and right 
upper bronchus obstruction and pleural effusion requiring en-
dobronchial prothesis and pleural drainage. Due to the rapid 
course of the disease, based on preliminary histology of poorly 
differentiated carcinoma, a dose-dense biweekly chemothera-
py with paclitaxel (175 mg/m2 d1), ifosfamide (2.5 g/m2 d1–3 
plus mesna), and cisplatin (70 mg/m2 d2) along with rhG-CSF 
rescue was started.
In the meantime, more detailed histochemical analyses were 
completed describing a mixture of necrotic and viable cells of 
variable size with high nuclear/cytoplasmic ratio and MIB-1 
Figure 1.  The first chest CT scan performed at the admission 
at the Division of Medical Oncology revealed a large 
(13.5×8 cm) right anterior upper mediastinal mass with 
extension into the right lobe.
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expression of approximately 60%. The majority of cells were 
dyshesive, with some focal cohesive growth pattern and no 
clear differentiation (Figure 2). A focal positivity was detected 
for cytokeratin 7 (CK7), Mouse Monoclonal Anti-Cytokeratin 
1 Antibody (MNF116), protein 63 (p63), CD10, and CD34. 
Molecular testing for the SYT gene rearrangement (18q11.2) 
by FISH, for the Epstein-Barr virus (EBV) (EBER probe) by in 
situ hybridization (ISH), for mutational status of the Epidermal 
Growth Factor Receptor (EGFR) (exons 18,19,21) and the Kirsten 
Rat Sarcoma Viral Oncogene Homolog (K-RAS) (exon 2) were 
all negative. On the basis of the clinical presentation, the rap-
id disease course and the histology, a diagnosis of NMC was 
suggested. Thus, NUT-fusion protein expression linked to the 
translocation t(15;19) was tested by a specific anti-NUT an-
tibody. The immunohistochemistry confirmed the hypothesis 
with 80% of nuclei showing a positive signal.
Surprisingly, a relevant clinical benefit was obtained after the 
first cycle of chemotherapy, with a progressive disappearance 
of palpable nodes and an improvement of all symptoms. The 
patient received a total of 6 dose-dense treatments with an 
expected hematological toxicity. At the end of chemotherapy, 
a total-body PET-CT scan showed a very good partial response 
with a reduction of the mediastinal bulk (2.6×1.8 cm), a com-
plete disappearance of lung lesions and pleural effusion, and a 
significant reduction of pathological nodes (Figure 3). The su-
perior mediastinal residual disease had a moderate dyshomo-
geneous fluorodeoxyglucose uptake.
Thirty-five days after the last cycle of chemotherapy, the pa-
tient started a radiation treatment targeting the initial medi-
astinal tumour area with a dose of 2 Gy/daily. Unfortunately, 
after 18 days and a total dose administered of 28 Gy, the pa-





Figure 2.  On hematoxylin-eosin staining, the neoplasia consisted of round (A ×20) and spindle (B ×20) atypical cells of large size, with 
prominent nucleoli, expressing cytokeratins (poorly differentiated carcinomas). Cytokeratins are pointed out by monoclonal 
broad spectrum antibody MNF116 and by monoclonal anticytokeratin antibody CK7 (C ×20), directed against low-molecular 
weight cytokeratins. The immunoreaction for anti-NUT (nuclear protein in testis) is positive in most of neoplastic cells (D ×20).
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and dyspnea. A new CT scan documented disease progression 
mainly outside of the radiation field with right pleural effu-
sion, peritoneal and retroperitoneal involvement, increase of 
bone lesions, and multiple subcutaneous nodules, but the ini-
tial mediastinal mass was still decreasing in size (Figure 4). At 
that time, considering that the pleural effusion was unilateral 
and the disease was progressing in several sites, we consid-
ered the fluid as a malignant pleural effusion, thus a diagnos-
tic thoracentesis was not performed.
Because of the rapid progression, based on pre-clinical data 
and after approval by the Local Ethics Committee, the patient 
stopped radiotherapy and entered into a compassionate use 
protocol with Romidepsin, a potent histone deacetylase (HDAC) 
inhibitor. The Local Ethics Committee approved the compas-
sionate use also on the basis of some preliminary encouraging 
data obtained with another HDAC inhibitor (Vorinostat) (French 
C., personal communication at that time and now on ref. [15]). 
Therefore, the patient received weekly intravenous doses of 
Romidepsin (14 mg/mq) for 3 doses. No significant toxicities 
were observed, but a PET/CT scan after the first course showed 
disease progression to the pleural ring, in the subcutaneous 
areas, nodal involvement, peritoneal and retroperitoneal car-
cinosis, and new bone lesions (Figure 5). On the basis of the 
pattern of progression suggestive for mesothelioma-like be-
havior, an empirically based treatment with Pemetrexed (500 
mg/mq every 3 weeks) was started. Unfortunately, the dis-
ease further progressed very rapidly and the patient eventu-
ally died after 1 course of Pemetrexed.
Discussion
When our patient was diagnosed with NMC, only 28 cases 
were reported in the literature and no successful treatment 
was yet identified [16]. According to the preliminary diagnosis 
Figure 3.  The chest CT scan performed at the end of the dose-
dense chemotherapy showed a very good partial 
response, with a reduction of the mediastinal bulk 
(2.6×1.8 cm).
Figure 5.  The chest CT scan performed after the first course 
of Romidepsin showed disease progression to the 
pleural ring and in the subcutaneous areas, and nodal 
involvement.
Figure 4.  The chest CT scan performed a few weeks after the 
end of radiotherapy on the initial mediastinal tumour 
area documented disease progression with right 
pleural effusion while the initial mediastinal mass was 
still decreasing in size.
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of undifferentiated carcinoma with high proliferative rate, we 
chose a dose-dense chemotherapy with Taxol, ifosfamide, and 
cisplatin delivered bi-weekly. After the first cycle of chemother-
apy, a significant clinical benefit was reported and during the 
next 5 cycles a progressive and considerable improvement was 
observed. Successive radiotherapy to the residual bulky mass 
was begun until extra-mediastinal progression.
Only a single case with a bone localized NMC has been re-
ported without disease at 34 months after diagnosis [17]. The 
patient was misdiagnosed in 1991 for a Ewing sarcoma and 
thus was treated with a combined modality therapy based on 
vincristine, doxorubicin, and ifosfamide alternating with cis-
platin, doxorubicin, and ifosfamide [18]. During cycles 1 and 
2, hyperfractionated accelerated radiotherapy was also ad-
ministered to the tumor area. This case suggests that inten-
sified regimens may generate a stable benefit for NMC, par-
tially validating our strategy and explaining the early results 
obtained in our patient. Unfortunately, a number of questions 
about the choice of chemotherapy treatment and proper tim-
ing still remain open.
This rapidly growing tumor demonstrated a surprising clin-
ical response to dose-dense chemotherapy. Particularly, the 
tumor showed a chemo-sensitivity profile comparable to that 
observed for Ewing sarcomas and germ cell tumors. These 
findings suggest a role for high-dose chemotherapy, possibly 
with stem cell transplantation, as a therapeutic option in NMC, 
as in fact previously described for Ewing sarcoma [19,20] and 
for germ cell tumors [21,22]. Based on these considerations, 
our patient’s hematopoietic stem cells were mobilized and 
harvested, but the extremely rapid disease progression did 
not allow performing any high-dose chemotherapy program. 
It must be noted, however, that NUT cells can positively stain 
for CD34 and this might compromise the identification of tu-
mor cells in the grafts.
Our case history also questions the role and timing of radiation 
therapy. Our patient received radiotherapy after 35 days from 
the end of chemotherapy and during the treatment the tumour 
progressed largely outside the radiation field and spread to 
distant sites. Interestingly, a case report of NMC treated with 
concomitant hyperfractionated accelerated radiotherapy and 
chemotherapy has been published [17], suggesting the possi-
bility of treating the primitive tumor mass and controlling the 
systemic disease at the same time.
The very good partial response obtained with dose-dense che-
motherapy in our patient raises the possibility of evaluating the 
efficacy of maintenance treatments with either prolonged and 
less toxic chemotherapy or biological agents. Based on a pre-
vious limited clinical experience with an FDA-approved HDAC 
inhibitor in a child with NUT midline carcinoma (French C., per-
sonal communication at that time and now ref. [15]), we decid-
ed to treat our patient with Romidepsin. Romidepsin is current-
ly being studied in a variety of tumors and in 2009 it was been 
approved by the US Food and Drug Administration (FDA) for 
the treatment of cutaneous T-cell lymphoma. Unfortunately, in 
this case the treatment with Romidepsin was ineffective, pos-
sibly because of primary resistance to the drug or secondary 
resistance mechanisms, including parallel pathway activation, 
overexpression of anti-apoptotic Bcl2 protein, drug-induced de 
novo genetic variations, or target protein/gene change.
Conclusions
The optimal treatment for NMC has still to be defined, part-
ly because of the rarity of the disease. Our case history adds 
some interesting findings to the available information: NMC 
can be, at least in part, chemosensitive and radiosensitive. This 
opens the possibility to study more aggressive treatments, in-
cluding high-dose consolidation chemotherapy, and to evalu-
ate the role of maintenance treatments with biological agents 
such as HDAC inhibitors or bromodomain inhibitors.
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